ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2932

Systemic Lupus Erythematosus Biomarkers Identified Using Multi-Omic and Artificial Intelligence Analysis through Interrogative Biology

Eric Grund1, Lixia Zhang1, Leonardo Rodrigues1, Viatcheslav Akmaev1, Rangaprasad Sarangarajan1, Michael Kiebish1, Niven Narain1 and Gary S. Gilkeson2, 1BERG, LLC, Framingham, MA, 2Department of Medicine, Medical University of South Carolina, Charleston, SC

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Auto-immunity, Biomarkers and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, October 24, 2018

Title: 6W010 ACR Abstract: SLE–Clinical V: Biomarkers, Criteria, & Outcomes (2928–2933)

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose:

Biomarkers for use in developing treatments and diagnostics for Systemic Lupus Erythematosus (SLE) are a large unmet need. The wide differential in patient progression and outcome for SLE calls for the identification of informative biomarkers for use in patient stratification and determining course of treatment. In this study we used Berg Interrogative Biology®, a platform technology integrating multi-omic (metabolomics, lipidomics and proteomics) and artificial intelligence (bAIcis®) technologies to discover serum and urine based candidate markers of lupus.

Methods:

This study was conducted using retrospectively collected and clinically annotated serum and urine samples from 166 patients (90 African American and 71 Caucasian). Medical data included demographic data, ACR classification criteria, SLICC-damage index, SLEDAI disease activity scores, lab data, and medication information. Omics data for Mass Spectrometry included serum proteomics, metabolomics and lipidomics, and urine proteomics and metabolomics. As part of Berg Interrogative Biology® technology, all clinical and omics datasets were processed and fully integrated in a harmonized dataset. The multi-omic/clinic dataset was analyzed by Berg Artificial Intelligence technology (bAIcis®) that uses data-driven methods to identify panels of Lupus candidate biomarkers, each with a target area under the ROC curve (AUC) of 0.8 with the minimal combination of up to 6 biomarkers. Biomarker panels were analyzed separately for each biomatrix. bAIcis® provided (1) a summary table with individual AUC, panel AUC, panel power, and number of samples participated; (2) a panel ROC curve; and (3) a diagnostic table with statistics: sensitivity, specificity, positive predicted value (PPV), negative predicted value (NPV), and odds ratio.

Results:

Biomarker panels in serum and urine were discovered for lupus vs non-lupus (2 biomarkers in serum with AUC 0.836 and 5 in urine with AUC 0.805), renal disease vs no renal disease (2 biomarkers in serum with AUC 0.848 and 2 in urine with AUC 0.844), scleroderma vs. non-scleroderma (2 biomarkers in serum with AUC 0.826 and 2 in urine with AUC 0.705), scleroderma vs. lupus (5 biomarkers in serum with AUC 0.831 and 3 in urine with AUC 0.771), SLICC stage <2 vs >=2 (4 biomarkers in serum with AUC 0.829 and 2 in urine with AUC 0.77), SLEDAI score <6 vs >=6 (2 biomarkers in serum with AUC 0.809 and 2 in urine with AUC 0.641), ANA (1 biomarkers in serum with AUC 0.604 and 2 in urine with AUC 0.73), and drug efficacy for Mycophenolate (2 biomarkers in serum with AUC 0.847 and 1 in urine with AUC 0.933).

Conclusion:

Biomarker panels with AUC > 0.8 and power > 0.8 will be pursued in further prospective clinical study with a larger subject number. The urine and serum biomarker panels for lupus vs no lupus, renal disease vs no renal disease, scleroderma vs no scleroderma, scleroderma vs lupus, SLICC stage, and drug efficacy for Mycophenolate are fit for further validation. Integrating multi-omic analysis with artificial intelligence identified several biomarker panels that meet numerous unmet needs for the identification and clinical stratification of Systemic Lupus Erythematosus.


Disclosure: E. Grund, BERG, LLC, 1, 3; L. Zhang, BERG, LLC, 1, 3; L. Rodrigues, BERG, LLC, 1, 3; V. Akmaev, BERG, LLC, 1, 3; R. Sarangarajan, BERG, LLC, 1, 3, 4; M. Kiebish, BERG, LLC, 1, 3; N. Narain, BERG, LLC, 1, 3, 4; G. S. Gilkeson, None.

To cite this abstract in AMA style:

Grund E, Zhang L, Rodrigues L, Akmaev V, Sarangarajan R, Kiebish M, Narain N, Gilkeson GS. Systemic Lupus Erythematosus Biomarkers Identified Using Multi-Omic and Artificial Intelligence Analysis through Interrogative Biology [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/systemic-lupus-erythematosus-biomarkers-identified-using-multi-omic-and-artificial-intelligence-analysis-through-interrogative-biology/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-lupus-erythematosus-biomarkers-identified-using-multi-omic-and-artificial-intelligence-analysis-through-interrogative-biology/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology